Glucose

Doran, W., Tunnicliffe, L., Muzambi, R., Rentsch, C. T., Bhaskaran, K., Smeeth, L., et al. (2024). Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. Bmj Open Diabetes Res Care, 12. http://doi.org/10.1136/bmjdrc-2023-003548

View

Lai, H. T. M., Chang, K., Sharabiani, M. T. A., Valabhji, J., Gregg, E. W., Middleton, L., et al. (2023). Twenty-year trajectories of cardio-metabolic factors among people with type 2 diabetes by dementia status in England: a retrospective cohort study. Eur J Epidemiol. http://doi.org/10.1007/s10654-023-00977-7

View

Brunetti, V. C., St-Jean, A., Dell'Aniello, S., Fisher, A., H. Y. Yu, O., Bugden, S. C., et al. (2022). Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. Bmc Endocr Disord, 22, 241. http://doi.org/10.1186/s12902-022-01140-1

View

Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437

View

Birkeland, K. I., Bodegard, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., et al. (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75-85. http://doi.org/10.1111/dom.14189

View